Emily B. Walling
Expertise in
2
conditions
Expertise in
2
conditions
1540 E Hospital Dr, Floor 7 Reception C, 
Ann Arbor, MI 

Overview

Emily B. Walling MD, MPHS is a Clinical Assistant Professor in the Division of Hematology/Oncology, Department of Pediatrics. Dr. Walling received her bachelor's degree from the University of Wisonsin-Madison and her medical degree from the University of Toledo. Following residency training in pediatrics at the Medical College of Wisconsin, Dr. Walling completed her fellowship training in pediatric hematology-oncology at Washington University where she earned her master's degree in population health sciences. Dr. Walling joined the faculty at Michigan in 2016. She founded and is the co-medical director of the Michigan Medicine Adolescent and Young Adult Oncology Program.

Dr. Walling is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Febrile Neutropenia, Classical Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Hepatoblastoma, and Bone Marrow Aspiration.

Dr. Walling is board certified in Pediatrics and Pediatric Hematology-Oncology. She is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 7 clinical trials. Dr. Walling is currently accepting new patients.

Specialties

Pediatrics

Licenses

Pediatrics in MI

Board Certifications

Pediatrics
Pediatric Hematology-Oncology

Fellowships

Washington University, Pediatric Hematology/Oncology, 2016

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

C. S. Mott Children's Hospital
1540 E Hospital Dr, Floor 7 Reception C, Ann Arbor, MI 48109

Additional Areas of Focus

Dr. Walling has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
View 5 Less Clinical Trials
Similar Doctors
Expertise in
1
conditions
Medical Genetics | Pediatrics
Expertise in
1
conditions
Medical Genetics | Pediatrics
Referral may be required

University Of Michigan Pediatric Genetics Clinic

1540 East Hospital Drive, Floor 6, 
Ann Arbor, MI 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients

Donna Martin is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Martin is highly rated in 1 condition, according to our data. Her clinical expertise encompasses CHARGE Syndrome and Neurofibromatosis Type 1 (NF1). Dr. Martin is board certified in American Board Of Medical Genetics And Genomics, Clinical Biochemical Genetics - 2023. Dr. Martin is currently accepting new patients.

Expertise in
14
conditions
Pediatrics | Internal Medicine
Expertise in
14
conditions
Pediatrics | Internal Medicine
Referral may be required

Pulmonary Clinic

1500 E Medical Center Dr, Floor 3 Reception C, 
Ann Arbor, MI 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients

Dr. Gregory Yanik has been a faculty member within the Blood and Marrow Transplant Program and Division at the University of Michigan since 1992. He was born and raised in the Detroit area, attended medical school at Wayne State University and trained in hematology-oncology at Cincinnati Children’s Hospital. He and his wife Marybeth have three grown children. Dr. Yanik has been the recipient of many prestigious awards in recognition of his contributions to medical research, clinical care, and education, including the Leland and Elaine Blatt Professorship of Pediatric Oncology, the University of Michigan Pediatric Teacher of the Year Award, and the Leukemia and Lymphoma Society Chairman’s Citation for Outstanding Service. Dr. Yanik is the founder of and chairs the Executive Committee for the Children’s Hematology Alliance of Michigan (CHAMI), a unique alliance of pediatric hematology/practice teams in the State of Michigan whose goal is to continuously improve the quality of care for children with these medical conditions regardless of where they are treated in the State. In addition to these many activities, Dr. Yanik makes time to serve on the Executive Committee for Make a Wish Michigan. Dr. Yanik is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Bronchiolitis Obliterans, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Graft Versus Host Disease (GvHD), and Lung Transplant. Dr. Yanik is currently accepting new patients.

Expertise in
33
conditions
Oncology | Pediatrics
Expertise in
33
conditions
Oncology | Pediatrics
Referral may be required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception A, 
Ann Arbor, MI 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Thyroid Cancer, Throat Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology. Dr. Worden is currently accepting new patients.

Frequently Asked Questions about Dr. Emily B. Walling

How do I make an appointment with Dr. Emily B. Walling?

You can book an appointment with Dr. Emily B. Walling by calling their office at 734-936-9814. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emily B. Walling a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emily B. Walling is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emily B. Walling specialize in?

While Dr. Emily B. Walling is a Pediatrics, they have specific expertise in Febrile Neutropenia, Classical Hodgkin Lymphoma, and Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Emily B. Walling participate in research or clinical trials?

Yes. Dr. Emily B. Walling has published 25 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Dr. Emily B. Walling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emily B. Walling accept my insurance?

Dr. Emily B. Walling accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 734-936-9814 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walling's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile